MIST · Insider Trading
Milestone Pharmaceuticals Inc. Common Shares
Every open-market purchase and sale reported by MIST officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-12 | Michael John Tomsicek | Director | A | +77,000 deriv. | — |
| 2026-06-12 | Joseph C Papa | Director | A | +77,000 deriv. | — |
| 2026-06-12 | Seth H. Z. Fischer | Director | A | +77,000 deriv. | — |
| 2026-06-12 | Lisa M. Giles | Director | A | +77,000 deriv. | — |
| 2026-06-12 | Robert James Wills | Director | A | +77,000 deriv. | — |
| 2026-06-12 | Andrew Saik | Director | A | +77,000 deriv. | — |
| 2026-06-12 | Stuart Duty | Director | A | +77,000 deriv. | — |
| 2026-04-20 | Joseph Oliveto | President and CEO | Sell | −36,500 | −$82.49K |
| 2026-02-05 | David Bharucha | Chief Medical Officer | A | +204,000 deriv. | — |
| 2026-02-05 | Jeffrey Edward Nelson | Chief Operating Officer | A | +204,000 deriv. | — |
| 2026-02-05 | Joseph Oliveto | President and CEO | A | +679,000 deriv. | — |
| 2026-02-05 | Lorenz Muller | Chief Commercial Officer | A | +204,000 deriv. | — |
| 2026-02-05 | Amit Hasija | CFO & EVP of Corp. Development | A | +204,000 deriv. | — |
| 2026-02-04 | Joseph Oliveto | President and CEO | A | +1,132,000 deriv. | — |
| 2026-02-04 | David Bharucha | Chief Medical Officer | A | +340,000 deriv. | — |
| 2026-02-04 | Jeffrey Edward Nelson | Chief Operating Officer | A | +340,000 deriv. | — |
| 2026-02-04 | Lorenz Muller | Chief Commercial Officer | A | +340,000 deriv. | — |
| 2026-02-04 | Amit Hasija | CFO & EVP of Corp. Development | A | +340,000 deriv. | — |
| 2026-01-28 | Amit Hasija | CFO & EVP of Corp. Development | MIXED | +49,848 | −$158.21K |
| 2026-01-28 | Lorenz Muller | Chief Commercial Officer | MIXED | +55,354 | −$145.85K |
| 2026-01-28 | Jeffrey Edward Nelson | Chief Operating Officer | MIXED | +49,848 | −$158.21K |
| 2026-01-28 | Joseph Oliveto | President and CEO | MIXED | +179,023 | −$375.31K |
| 2026-01-28 | David Bharucha | Chief Medical Officer | MIXED | +49,848 | −$158.21K |
| 2026-01-09 | Joseph Oliveto | President and CEO | Sell | −43,500 | −$97.88K |
| 2025-12-11 | Lorenz Muller | Chief Commercial Officer | G | −25,000 | — |
| 2025-07-15 | Lorenz Muller | Chief Commercial Officer | A | +66,666 | — |
| 2025-07-15 | Debra K. Liebert | Director | A | +16,666 | — |
| 2025-07-15 | Robert James Wills | Director | A | +50,000 | — |
| 2025-07-15 | David Bharucha | Chief Medical Officer | A | +53,333 | — |
| 2025-07-15 | Joseph Oliveto | President and CEO | A | +66,666 | — |
| 2025-07-15 | Amit Hasija | CFO & EVP of Corp. Development | A | +50,000 | — |
| 2025-07-15 | Joseph C Papa | Director | A | +100,000 | — |
| 2025-06-12 | Seth H. Z. Fischer | Director | A | +40,000 deriv. | — |
| 2025-06-12 | Andrew Saik | Director | A | +40,000 deriv. | — |
| 2025-06-12 | Michael John Tomsicek | Director | A | +40,000 deriv. | — |
| 2025-06-12 | Robert James Wills | Director | A | +40,000 deriv. | — |
| 2025-06-12 | Stuart Duty | Director | A | +40,000 deriv. | — |
| 2025-06-12 | Lisa M. Giles | Director | A | +40,000 deriv. | — |
| 2025-06-12 | Joseph C Papa | Director | A | +40,000 deriv. | — |
| 2025-01-29 | Jeffrey Edward Nelson | Chief Operating Officer | A | +201,000 deriv. | — |
| 2025-01-29 | Lorenz Muller | Chief Commercial Officer | A | +201,000 deriv. | — |
| 2025-01-29 | David Bharucha | Chief Medical Officer | A | +201,000 deriv. | — |
| 2025-01-29 | Joseph Oliveto | President and CEO | A | +666,000 deriv. | — |
| 2025-01-29 | Amit Hasija | CFO & EVP of Corp. Development | A | +201,000 deriv. | — |
| 2024-09-05 | Joseph C Papa | Director | A | +80,000 deriv. | — |
| 2024-08-29 | Lisa M. Giles | Director | A | +40,000 deriv. | — |
| 2024-08-29 | Seth H. Z. Fischer | Director | A | +40,000 deriv. | — |
| 2024-08-29 | Michael John Tomsicek | Director | A | +40,000 deriv. | — |
| 2024-08-29 | Robert James Wills | Director | A | +40,000 deriv. | — |
| 2024-08-29 | Stuart Duty | Director | A | +40,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Joseph Oliveto | President and CEO | 446,244 | $287.56K |
| Lorenz Muller | Chief Commercial Officer | 196,486 | $126.62K |
| David Bharucha | Chief Medical Officer | 125,426 | $80.82K |
| Joseph C Papa | Director | 100,000 | $64.44K |
| Jeffrey Edward Nelson | Chief Operating Officer | 100,000 | $64.44K |
| Amit Hasija | CFO & EVP of Corp. Development | 91,993 | $59.28K |
| Robert James Wills | Director | 65,000 | $41.89K |
| Debra K. Liebert | Director | 20,793 | $13.40K |
| Michael John Tomsicek | Director | 15,000 | $9.67K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MIST quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.